Profound Medical Celebrates The Hong Center's 200th Independent TULSA Procedure for Prostate Disease

Core Insights - Profound Medical Corp. has achieved a significant milestone with the TULSA Procedure, marking the first 200 procedures performed independently by a urologist without radiologist involvement, establishing a new model for MRI-guided prostate therapy [1][2][3] Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on developing and marketing AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue [5][6] - The company is commercializing the TULSA-PRO® system, which combines real-time MRI, AI-enhanced planning, and robotically-driven ultrasound for precise prostate treatment [6][7] TULSA Procedure Details - The TULSA Procedure is a clinically proven treatment for prostate disease that utilizes robotically controlled ultrasound to ablate prostate tissue while preserving surrounding structures [2][6] - This procedure is performed in a single session, takes a few hours, and does not require hospitalization, with most patients reporting quick recovery [6][7] - The TULSA Procedure is designed to treat a wide range of prostate conditions, including low-, intermediate-, and high-risk prostate cancer, benign prostatic hyperplasia (BPH), and salvage therapy for radio-recurrent localized prostate cancer [6][8] Clinical Impact - Dr. Y. Mark Hong's independent execution of the TULSA Procedure demonstrates that urologists can safely perform the entire procedure, achieving excellent outcomes without the need for radiologist collaboration [2][3] - The procedure has shown to result in high cure rates, rapid recovery, and preservation of urinary and sexual function, with no procedural blood loss [3][4] Future Outlook - Dr. Hong believes that the TULSA Procedure represents the future of prostate disease treatment and may eventually replace radical prostatectomy as the first-line option for prostate cancer [4]